Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)

General Inclusion Criteria: * Patient age ≥ 18 and ≤ 85 years * Patient understands the trial requirements and treatment procedures and provides informed consent prior to any trial-specific tests or treatment * Patients with CCS (stable angina, chronic angina, and chronic coronary artery disease) or ACS (unstable angina, ST-elevated myocardial infarction, and non-ST-elevated myocardial infarction) indicated for a percutaneous intervention with stent implantation. Angiographic Inclusion Criteria: * Patient has ≤ 3 lesions planned to be treated during the index procedure, each in a native epicardial vessel (including up to 1 planned Non-Target Lesion). 1. Treatment is limited to a maximum of 2 Target Lesions per epicardial vessel. Any planned Non-Target Lesion must be located in a separate vessel from Target Lesion(s). 2. When treatment of 2 target lesions in a single epicardial vessel is planned, there must be adequate separation between lesions to ensure a gap of greater than or equal to 10 mm between study devices. 3. If a planned Non-Target Lesion is present it must have been treated without complication\* prior to randomization. 4. The definition of epicardial vessels is the LAD, LCx and RCA, and is inclusive of their branches. * Target Lesion vessel diameter(s) and lesion length(s) suitable for implantation with either study device (DynamX Bioadaptor or Control) using a single device per lesion. * Successful pre-dilatation of a minimum of 1 Target Lesion, defined as no waist in the inflated pre-dilatation balloon (using two orthogonal views) with a pre-dilatation balloon diameter size approximately 0.25 mm smaller than reference vessel diameter but not more than 0.5 mm smaller than the reference vessel diameter. A residual diameter stenosis prior to study device implantation by visual estimate is recommended to be \< 30%. General Exclusion Criteria: * Acute myocardial infarction with Killip class III and IV * Known history of chronic heart failure with LVEF \< 30% * Life expectancy \< 2 years * Patients on renal dialysis or with known eGFR \< 30 ml/min * Planned surgery necessitating interruption of dual antiplatelet therapy within 6 months after the index procedure * Known intolerance to components of the study device or control stent or medication required (e.g. intolerance to concomitant anticoagulation or antiplatelet therapy) * Patient has a current diagnosis of active COVID-19 disease * Patient is currently participating in another clinical trial with an investigational device or an investigational drug that has the potential to impact study results (such as, anti-thrombotic or anti-platelet medications) that has not yet completed its primary endpoint * Known pregnancy or breastfeeding * Patient is, in the opinion of the Investigator, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason * Subject has undergone prior PCI in a target vessel during the last 12 months. (A target lesion can be randomized and treated if a vessel contains a stent older than 12 months if the stent is more than 10 mm from the intended target lesion.) Angiographic Exclusion Criteria: * Lesions in the left main artery * Venous or arterial bypass grafts * In-stent restenosis * Chronic total occlusion * Ostial lesions (\< 3 mm of the ostium of the RCA, LAD or LCx) * Prior stent located in a Non-Target Vessel \< 48 hours prior to the index procedure * Lesion with severe calcification and/or tortuosity requiring the planned use of a guide extension catheter, rotablation or atherectomy * Bifurcation lesions requiring a planned 2 or more stent technique